3561 results for «372»
3561 results
TAV-in-SAV - Part 1
08 Feb 2025 – From PCR Tokyo Valves 2025
Delve into the complex world of TAV-in-SAV (Transcatheter Aortic Valve-in-Surgical Aortic Valve) in this comprehensive session. Explore various case studies, including valve-in-valve TAVI in a patient with structural valve deterioration, a successful case of balloon-assisted BASILICA for TAV-in-TAV, and TAVI after valve sparing aortic replacement. Gain...
Lifetime management - First valve choice matters
08 Feb 2025 – From PCR Tokyo Valves 2025
In this expert-led session, explore new frontiers in TAVI, focusing on bicuspid aortic valves, small annulus, and the risk of secondary interventions. Gain insights from the latest randomized trials (RHEIA) and registry data (CAvEAT), with real-world case discussions highlighting their clinical impact.
TAVI complex cases: intravascular hemolysis, Heyde syndrome & more
08 Feb 2025 – From PCR Tokyo Valves 2025
This session presents a diverse array of complex TAVI cases, from interventions for paravalvular leak-induced intravascular hemolysis to cases of severe aortic tortuosity, calcification hindering valve expansion, and successful TAVI in patients with Heyde syndrome and HIV infection. Gain valuable insights into navigating these challenging scenarios.
Management of paravalvular leak
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore this comprehensive session on the management of paravalvular leaks, a challenging complication following surgical or transcatheter valve replacements. Discover insights into managing post-operative pulmonary edema, percutaneous closure of left ventricular septal defects, and the nuances of mitigating recurrent paravalvular leaks. Dive into complex cases involving...
Post-procedure complications: leaflet thrombus, hemolytic anemia & more
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore this session to discover a range of post-procedure complications that can arise after TAVI, including subacute leaflet thrombus, hemolytic anemia after surgical aortic valve replacement, late migration of papillary fibroelastoma, sinus sequestration, delayed left main occlusion, and high-grade atrioventricular block. Additionally, learn about techniques to...
TAVI and coronary artery disease
08 Feb 2025 – From PCR Tokyo Valves 2025
Delve into the complex interplay between TAVI and coronary artery disease in this comprehensive session. Explore the decision-making process for optimal sequencing of PCI and TAVI, and examine cases of acute myocardial infarction due to coronary embolism and delayed coronary obstruction following TAVI. Gain insights into...
Redo mitral procedures
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore this session to gain insights into the management of recurrent mitral regurgitation after percutaneous mitral valve interventions. Discover various redo procedures, including the use of the PASCAL system for recurrent MR after MitraClip, redo M-TEER for torn posterior leaflet, and successful redo TEER and MitraClip...
High-risk TAVI
08 Feb 2025 – From PCR Tokyo Valves 2025
Delve into the management of high-risk TAVI cases in this session. Discover innovative approaches, such as Impella-assisted TAVI in severe bicuspid aortic valve disease with severe left ventricular dysfunction, TAVR for pure native aortic regurgitation in surgically unfit patients, and the use of TAVI as a...
TAV-in-TAV cases
08 Feb 2025 – From PCR Tokyo Valves 2025
Explore this session to delve into the complexities and challenges of TAV-in-TAV procedures. Gain insights into various case studies, including a successful TAV-in-TAV with coronary protection, a case of CABG and TAV-in-TAV, TAVI in a patient with failed homograft and three previous sternotomies, and concurrent mitral...
The value of WATCHMAN therapy - Who should we treat?
08 Feb 2025 – From PCR Tokyo Valves 2025
Delve into the value of WATCHMAN therapy in this sponsored session by Boston Scientific. Explore the latest evidence and future perspectives of this innovative treatment option. Understand who the ideal patient is for WATCHMAN therapy and how to identify them in daily clinical practice, including TAVI...
Standardised implant technique with self-expandable valve
08 Feb 2025 – From PCR Tokyo Valves 2025
Don’t miss this PCR Tokyo Valves 2025 session replay, where leading experts share key techniques for simplifying and optimising TAVI procedures with the Evolut device. This session covers essential insights into safely performing procedures on patients with various anatomical types using the self-expandable valve, while emphasising...
Mitral valve-in-valve and valve-in-ring electrosurgery
08 Feb 2025 – From PCR Tokyo Valves 2025
Coronary complications: sharing the unusual ones
23 May 2025 – From EuroPCR 2025
This session shares unusual coronary complications including microcatheter tip entrapment, balloon shaft fracture, coronary balloon rupture salvage, and retained equipment retrieval, highlighting innovative solutions and procedural vigilance.
Coronary sinus reducer for microvascular angina
28 Feb 2020
A 61-year-old man with a history of 2-vessel coronary artery stenting, hypertension and type-2 diabetes mellitus was admitted 5 times within September 2017 and November 2018 for recurrent angina CCS class III-IV refractory to therapy with nitrates, b-blockers and ranolazine in maximally tolerated doses...
Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation – The WATCH-TAVR Trial
26 Oct 2023
Panos Xaplanteris provides his take on WATCH-TAVR results which were presented by Samir R. Kapadia at TCT Congress 2023.
Safety and Efficacy of Left Atrial Appendage Occlusion at the Time of Transcatheter Aortic Valve Replacement - The WATCH TAVR Trial
Author
EuroPCR 2019 Press Release: A pragmatic approach to defining high bleeding risk for patients undergoing in PCI
22 May 2019
Paris, France, 22 May 2019. Identification and management of patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) is of major importance, but a lack of standardisation in defining this population limits trial design, data interpretation, and clinical decision-making.
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
SCOPE I: A randomized trial of the ACURATE Neo vs. the SAPIEN 3 bioprosthesis in patients with severe aortic stenosis - TCT 2019
28 Sep 2019
The results of the SCOPE I trial were presented at TCT 2019 in San Francisco by Jonas Lanz, Bern University Hospital. Read the analysis by Fabien Praz.
Author
EuroPCR 2019 Press Release: Education rhymed with interaction at the world-leading course in interventional cardiovascular medicine
24 May 2019
Paris, France, 24 May 2019. A total of 11,206 participants from over 120 different countries were present at the 30th edition of EuroPCR. An additional 4,700 online learners connected to watch a selection of sessions that were made available both live and on replay via PCR...
Five-year outcomes of the randomised trial of fractional flow reserve guided PCI compared to coronary artery bypass grafting: FAME 3
02 Apr 2025
Kalaivani Mahadevan provides her take on the five-year outcomes of the FAME 3 trial presented by William F. Fearon at ACC.25 in Chicago.
Author
